Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miguel Mercado

Urology Tomball, TX Medical Doctor

NPI 1700102704 CMS profile 304517

506 Graham Dr Ste 150, Tomball, TX 77375

Open in the dashboard

General payments

$17,799

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miguel Mercado of Tomball, TX is reported in the CMS Open Payments database as having received $17,799 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,203 66
2024 General $1,611 71
2023 General $1,634 37
2022 General $1,936 28
2021 General $816 18
2020 General $4,252 40
2019 General $4,347 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miguel Mercado
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Miguel Mercado were reported at $3,203. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Miguel Mercado Urology median Middle half National median
2019 $4,347 $480 $147–$1,201 $163
2020 $4,252 $246 $87–$645 $114
2021 $816 $358 $111–$1,000 $132
2022 $1,936 $476 $143–$1,263 $149
2023 $1,634 $560 $168–$1,461 $160
2024 $1,611 $563 $170–$1,464 $164
2025 $3,203 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,888 65 payments
  2. Teleflex LLC $2,616 11 payments
  3. Coloplast Corp $1,921 28 payments
  4. Axonics Modulation Technologies, Inc. $1,465 26 payments
  5. Sumitomo Pharma America, Inc. $619 68 payments
  6. Astellas Pharma US Inc $307 14 payments
  7. TissueTech, Inc. $295 8 payments
  8. Olympus America Inc. $293 2 payments
  9. Accord Healthcare, Inc. $221 9 payments
  10. Endo USA, Inc. $216 12 payments
  11. Other $1,957 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,250 302 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,275 4 payments
  3. Travel and Lodging $1,144 2 payments
  4. Education $131 5 payments
Products named General payments · program years 2019–2025
  1. GENERAL - BPH $3,054 6 payments
  2. General BPH $2,452 8 payments
  3. UROLIFT Interventional Urology $1,801 3 payments
  4. BARRIGEL $1,424 3 payments
  5. Axonics $1,405 23 payments
  6. GEMTESA $702 72 payments
  7. GREENLIGHT $678 17 payments
  8. Titan $647 14 payments
  9. UROLIFT Interventional Urology $431 10 payments
  10. AMS $424 4 payments
  11. Other $6,156 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

4,440

Median for Urology: 1,053

Drug cost

$515,132

Median for Urology: $101,464

Branded share of claims

30.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 440 $339,063
Myrbetriq Mirabegron Brand 167 $96,199
Tamsulosin Hcl Generic 1,306 $14,968
Oxybutynin Chloride Er Oxybutynin Chloride Brand 461 $9,980
Solifenacin Succinate Generic 66 $7,699
Finasteride Generic 557 $7,526
Testosterone Cypionate Generic 139 $6,815
Methenamine Hippurate Generic 87 $6,624
Estradiol Generic 57 $4,281
Potassium Citrate Er Potassium Citrate Brand 44 $3,931

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$239,961

Of which drugs: $19,069

Medicare patients

623

Average age 74

Services billed

3,788

116 women, 507 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 43%
Diabetes 34%
Chronic kidney disease 30%
Cancer 30%
Atrial fibrillation 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 11 72 $10,255
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 14 40 $80

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $273
$273 440 —
XIAFLEX
  • Endo USA, Inc. $68
  • Endo Pharmaceuticals Inc. $40
$108 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $60
$60 — —
XTANDI
  • Astellas Pharma US Inc $43
  • PFIZER INC. $7
$50 — —
XYOSTED
  • Antares Pharma, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record